News | Stents Peripheral | December 13, 2016

Biotronik Showcases Positive Results for Pulsar-18 Stent in the Superficial Femoral Artery

Twelve-month interim results show 75 percent primary patency rate, 93.1 percent freedom for target lesion revascularization

Biotronik, Pulsar-18 bare metal self-expanding stent, BMS SE, BIOFLEX PEACE trial, 12-month results, VEITHsymposium 2016

December 13, 2016 — Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal self-expanding stent (BMS SE) at VEITHsymposium 2016, Nov. 15-19 in New York. Jos C. van den Berg, University of Bern, Switzerland, presented the encouraging interim results for Pulsar-18 in treatment of superficial femoral artery (SFA) disease during the symposium’s main program on behalf of lead investigator for the BIOFLEX PEACE all-comers trial, Michael Lichtenberg, Vascular Center, Arnsberg, Germany.

BIOFLEX PEACE is a prospective, multi-center registry examining 151 all-comers; the primary endpoint is primary patency at 12 months. The available 12-month interim results demonstrate that Pulsar-18 is an effective treatment option in the SFA. The primary patency rate of 75 percent and freedom from target lesion revascularization (TLR) of 93.1 percent confirm the results of previous Pulsar studies.1,2 Clinical success of 85 percent (defined as improvement in Rutherford class ≥1) has also been observed.

“It is reassuring to see that the clinical outcomes in this real world registry are similar to already published 12-month data,” stated van den Berg. “These positive results were obtained with the Pulsar stent, which has a thin strut design producing a low chronic outward force (COF). As higher COF has been shown to result in higher restenosis rates3, Pulsar’s unique design can be combined with minimal oversizing to further reduce COF for better outcomes.

Pulsar stents are manufactured with Biotronik’s proBIO coating, a silicon carbide layer that reduces metal ion release from the stent surface into the surrounding tissue. Pulsar-18 is available in diameters of 4 to 7 mm, all deliverable through a 4 F sheath.

The Pulsar-18 stent is an investigational device limited by United States law to investigational use.

For more information: www.biotronik.com

References:

1. Bosiers M et al. J Endovasc Ther. 2013, 20(6).

2. Lichtenberg M et al. J Endovasc Ther. 2014, 21(3).

3. Zhao H et al. Cardiovasc Intervent Radiol. 2009, 32(4).


Related Content

Feature | Stents Peripheral | Dave Fornell, Editor

November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) ...

Home November 06, 2019
Home
Technology | Stents Peripheral

October 5, 2018 — Veryan Medical Ltd has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System ...

Home October 05, 2018
Home
News | Stents Peripheral

April 27, 2018 — Intact Vascular Inc. recently closed a Series C financing totaling $20 million. This financing is ...

Home April 27, 2018
Home
News | Stents Peripheral

July 26, 2017 — Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee ...

Home July 26, 2017
Home
News | Stents Peripheral

July 14, 2017 — Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational ...

Home July 14, 2017
Home
News | Stents Peripheral

April 28, 2017 — Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting ...

Home April 28, 2017
Home
News | Stents Peripheral

March 16, 2017 — W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular ...

Home March 16, 2017
Home
News | Stents Peripheral

March 2, 2017 — Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee ...

Home March 02, 2017
Home
News | Stents Peripheral

December 8, 2016 — LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow ...

Home December 08, 2016
Home
Technology | Stents Peripheral

August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L. Gore & Associates’ Gore ...

Home August 02, 2016
Home
Subscribe Now